STOCK TITAN

UroGen Pharma to Present at Ladenburg Thalmann Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

UroGen Pharma Ltd (Nasdaq:URGN), a biopharmaceutical company specializing in treatments for urologic diseases and specialty cancers, will present at the Ladenburg Thalmann Healthcare Conference on July 14, 2021, at 12:00 PM ET. A live webcast of the event will be accessible on the Investors section of UroGen's website. The company is known for its innovative RTGel™ technology, enhancing drug delivery for bladder cancer treatments, including its investigational product UGN-102. The webcast replay will be available for 30 days.

Positive
  • None.
Negative
  • None.

UroGen Pharma Ltd (Nasdaq:URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that it will present at the Ladenburg Thalmann Healthcare Conference on July 14, 2021 at 12:00pm Eastern Time.

A live webcast of the presentation will be available on the Investors section of UroGen's website, www.urogen.com. A replay of each webcast will be available on the website for approximately 30 days.

About UroGen Pharma Ltd.

UroGen is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options. UroGen has developed RTGel™ reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen’s first commercial product, and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with low-grade non-muscle invasive bladder cancer, are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.urogen.com to learn more or follow us on Twitter, @UroGenPharma.

FAQ

What is the date of UroGen Pharma's presentation at the Ladenburg Thalmann Healthcare Conference?

The presentation is scheduled for July 14, 2021.

What time will the UroGen Pharma presentation take place?

The presentation will take place at 12:00 PM Eastern Time.

Where can I watch the UroGen Pharma presentation live?

You can watch the live webcast on the Investors section of UroGen's website.

What technology does UroGen Pharma use for drug delivery?

UroGen Pharma utilizes RTGel™, a proprietary hydrogel-based platform technology.

What is UGN-102 and its purpose?

UGN-102 is an investigational treatment for low-grade non-muscle invasive bladder cancer.

UroGen Pharma Ltd. Ordinary Shares

NASDAQ:URGN

URGN Rankings

URGN Latest News

URGN Stock Data

449.00M
37.83M
9.18%
92.27%
15.27%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
RA'ANANA